GitLab Option Alert: Jan, 2027 $55 Puts at the Bid: 1500 vs 2 OI; Earnings 3/3 After Close 

GitLab Option Alert: Jan, 2027 $55 Puts at the Bid: 1500 @ $9.1 vs 2 OI; Earnings 3/3 After Close Ref=$67.045

GitLab (NASDAQ:GTLB) 주식

GITLAB INC-CL A

GitLab

GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.

What Happened

Equities

News

Markets

ETFs

AAPL

ARKK

ARKW

CRWV

GTLB

HOOD

월요일(31일) 캐시 우드가 이끄는 아크 인베스트가 코어위브(NASDAQ:CRWV)와 로빈후드 마켓츠(NASDAQ:HOOD)와 관련해 주목할 만한 거래를 진행했다.

아크 인베스트, IPO 이후 급락한 코어위브 주식 360만 달러 규모 매입

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

ARKG

IRDM

캐시 우드의 화요일 대형 거래: 아크 인베스트는 템퍼스AI 주가 하락 속 780만 달러 투자

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

ARKF

CDNA

IBTA

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

GitLab Inc

Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.5, with a high estimate of $90.00 and a low estimate of $71.00. Experiencing a 5.11% decline, the current average is now lower than the previous average price target of $81.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544928_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Trex Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collin Verron</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeffrey Stevenson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Kurt Yinger</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rafe Jadrosich</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Trex Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Trex Co compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Trex Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Trex Co's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TREX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Trex Co analyst ratings.</a>
<h2>About Trex Co</h2>
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
<h3>Trex Co: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Trex Co faced challenges, resulting in a decline of approximately -14.36% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Trex Co's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Trex Co's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.3.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TREX

Analyst Expectations For Trex Co's Future

Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $59.0, a high estimate of $65.00, and a low estimate of $57.00. A decline of 3.28% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544883_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Harrow among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Harrow. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Harrow compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Harrow's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Harrow's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HROW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harrow analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Harrow</h2>
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
<h3>Financial Insights: Harrow</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Harrow showcased positive performance, achieving a revenue growth rate of 83.83% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Harrow's net margin excels beyond industry benchmarks, reaching 10.14%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Harrow's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Harrow's ROA stands out, surpassing industry averages. With an impressive ROA of 1.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 3.29, Harrow faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HROW

Where Harrow Stands With Analysts

In the last three months, 19 analysts have published ratings on Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $237.63, a high estimate of $260.00, and a low estimate of $190.00. This current average reflects an increase of 6.48% from the previous average price target of $223.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544869_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Zscaler among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$233.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zscaler. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zscaler compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zscaler's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Zscaler's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zscaler analyst ratings.</a>
<h2>Delving into Zscaler's Background</h2>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
<h3>Zscaler: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Zscaler showcased positive performance, achieving a revenue growth rate of 23.41% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.51%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Zscaler's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Zscaler's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Zscaler Stands With Analysts

Ratings for Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.2, along with a high estimate of $21.00 and a low estimate of $14.40. This current average represents a 9.54% decrease from the previous average price target of $20.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544860_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Macerich's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$14.40</td>
<td>$16.70</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macerich. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macerich compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Macerich's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MAC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macerich analyst ratings.</a>
<h2>All You Need to Know About Macerich</h2>
Macerich invests in premium mall assets. The company owns 30 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.9 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in December 2024.
<h3>Macerich: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Macerich displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 14.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Macerich's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -77.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Macerich's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.03%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Macerich's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.62%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Macerich's debt-to-equity ratio is below the industry average at 1.84, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Macerich

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 10 years by 4.68% on an annualized basis producing an average annual return of 15.15%. Currently, Aon has a market capitalization of $86.14 billion. 
Buying $1000 In AON: If an investor had bought $1000 of AON stock 10 years ago, it would be worth $4,076.56 today based on a price of $398.81 for AON at the time of writing.
<h3>Aon's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743544851_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.1, accompanied by a high estimate of $29.00 and a low estimate of $11.00. Highlighting a 14.76% decrease, the current average has fallen from the previous average price target of $20.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544820_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Myriad Genetics</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Breaking Down Myriad Genetics's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.12%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Myriad Genetics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

10 Analysts Assess Myriad Genetics: What You Need To Know

In the current session, the stock is trading at $264.54, after a 0.03% spike. Over the past month, Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) stock increased by 3.46%, and in the past year, by 15.49%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1743544819_0.png" alt="Past Year Chart" />

<h3>Evaluating Travelers Companies P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Travelers Companies has a lower P/E than the aggregate P/E of 17.76 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743544819_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Travelers Companies

The Company has agreed to pay certain fees and costs associated with the review to avoid costs of litigation.
The resolution is within an accrued amount established by the Company more than two years ago. As a result, there is no current or future financial impact to the Company or its subsidiaries.

Legal

Universal Insurance Reports Conclusion Of Claim Data Review Related To Hurricane Irma, Which Occurred In September 2017; Conclusion Includes State's Full And Final Dismissal Of Former Employee's Assertions

Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) has outperformed the market over the past 5 years by 13.43% on an annualized basis producing an average annual return of 29.63%. Currently, Occidental Petroleum has a market capitalization of $46.23 billion. 
Buying $100 In OXY: If an investor had bought $100 of OXY stock 5 years ago, it would be worth $378.38 today based on a price of $49.19 for OXY at the time of writing.
<h3>Occidental Petroleum's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743543909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Occidental Petroleum Stock In The Last 5 Years

AMZE

Amaze Expands Partnership With Adobe Express Through New Add-On Experience

President Donald Trump's tariff announcements are expected on Wednesday, April 2, which he is calling "Liberation Day." Though details of his plan remain unclear, the president has said the tariffs are intended to strengthen the U.S. economy and bolster <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs">American manufacturing. </a>
What To Know: Trump has predicted tariffs on goods coming into the U.S. will lead to investments in domestic manufacturing and companies reshoring their supply chains. Here's a look at some companies that could benefit from large-scale reshoring efforts. 
Read Next:<a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase"> Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;
Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) is the world's largest manufacturer of construction equipment and could benefit from a potential <a href="https://www.benzinga.com/content/43693234/will-the-tariff-bump-lead-to-a-steel-trap">construction boom</a> if more companies build factories and facilities in the U.S. 
CEO Jim Umpleby highlighted Caterpillar's position in the face of tariffs on the company's earnings call in January.&nbsp;
"We are a global manufacturer, but our largest manufacturing presence is in the U.S., and we are a net exporter outside of the U.S. and that positions us pretty well versus many other companies out there," said Umpleby. 
Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) is a pure-play industrial automation company that could see an increase in demand for its factory floor-level devices, such as motors, drives, sensors and relays if large-scale industrial reshoring occurs. 
Rockwell CEO Blake Moret expressed confidence Rockwell is in a strong position to minimize the impact of the tariffs in prepared remarks released with the company's most recent <a href="https://www.benzinga.com/pressreleases/25/02/b43588368/rockwell-automation-reports-first-quarter-2025-results">earnings report</a>.  
"Undoubtedly, there will be near-term disruptions and volatility in the global supply chain, both for us and our customers, but we continue to believe Rockwell is a net beneficiary of policies that increase U.S. manufacturing," said Moret. 
"Nobody is better positioned than Rockwell to help American manufacturers create the future of industrial operations,&#8221; Moret added.
More Stocks To Watch: Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) is an aerospace systems provider and data center technology innovator, which positions the company to capitalize on both tariff-related industrial modernization and the AI revolution's escalating power needs.
Fastenal Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) distributes construction, industrial and safety supplies and could see a pop if companies begin to reshore manufacturing and industrial supply chains as Trump's tariffs go into effect. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44575292/trump-to-target-dirty-15-countries-with-tariffs-which-countries-could-be-included">Trump To Target &#8216;Dirty 15&#8217; Countries With Tariffs: Which Countries Could Be Included?</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Government

Politics

Management

Global

Economics

FAST

Trump's Tariffs Could Spark Reshoring Boom For These 4 US Stocks

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 5.24% on an annualized basis producing an average annual return of 13.34%. Currently, American Tower has a market capitalization of $102.58 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $12,191.11 today based on a price of $219.44 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743543014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Earnings

SBFM

Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY

For 2025, the Company's full year expectations are calculated based on anticipated net premiums earned of approximately $184 million.

Guidance

KINS

Kingstone Reiterates 2025 Guidance, EPS At $1.75 - $2.15 (Est $1.48)

Victor Brodsky, the Company's Chief Accounting Officer, along with Meryl Golden, President and Chief Executive Officer, will assume the responsibilities of Chief Financial Officer upon Jennifer Gravelle's departure.

Kingstone Companies CFO Jennifer Gravelle Resigns Effective April 18, 2025, To Pursue Other Opportunities

The Investment satisfies all remaining requirements from both the U.S. Department of Energy and GM to satisfy all remaining equity capital fundraising requirements under the previously announced $2.26 billion loan from the DOE.
The JV Partners announced FID for construction of Phase 1 of Thacker Pass. Completion of Phase 1 of Thacker Pass is targeted for late 2027.

Lithium Americas Closes Strategic Investment From Orion; Announces FID For Thacker Pass Phase 1

I have been digging through J.P. Morgan&#8217;s latest annual energy report. Let me tell you, it&#8217;s a bucket of cold water for anyone believing we are about to flip a switch and transform our energy system overnight.
Michael Cembalest&#8217;s 15th annual energy paper, &#8220;Heliocentrism,&#8221; offers a sobering reality check that reminds me of buying value stocks when everyone else is chasing the latest tech darling. Sometimes, the boring truth matters more than the exciting story.
Despite all the headlines and $9 trillion spent globally over the last decade on wind, solar, electric vehicles, and energy storage, the renewable transition is moving at a snail&#8217;s pace—just 0.3% to 0.6% per year in terms of final energy consumption. 
Two great income stocks show why.
This is not the exponential S-curve adoption we see in technology. This old-school, grinding industrial transition takes decades, not years. Europe leads the pack with renewable share growing at 0.6% annually, followed by China at 0.4% and the US at a measly 0.3%.
At this pace, even Europe, the global leader, needs about 20 years to reach a 30% renewable share. That is not disruption; that is evolution.
Solar capacity is indeed booming, doubling over the past three years and projected to double again by 2027. Solar accounted for about 60% of new global capacity additions this year and might hit 75% by 2027.
But here is the catch that most headlines miss: due to capacity factors of just 15-20%, solar&#8217;s actual share of electricity generation is far smaller than the capacity numbers suggest.
Solar power provides about 7% of global electricity generation today.
Electricity itself?
That is only about a third of final energy consumption in most countries. The rest is direct fuel for transport, industrial production and heating.
When you boil it all down, solar power accounts for roughly 2% of global final energy consumption. Not exactly revolutionizing the system overnight, is it?
One of the tightest economic relationships is the connection between a country&#8217;s per capita GDP and energy consumption.
Human prosperity is built on steel, cement, ammonia/fertilizer, plastics, glass, chemicals and other industrial products that are incredibly energy-intensive to produce.
These industries rely on fossil fuels for 80-85% of their energy needs. This is not changing quickly, no matter what solar capacity charts show.
LinkedIn is filled with academics posting whenever wind, solar, and hydro meet most of a region&#8217;s power demand on a particular day. It is like reading a newspaper that only reports on baseball games where catchers hit home runs.
It happens sometimes, but it is not the norm.
In California, renewables plus storage met 75% or more of the load in only 26% of all hours in 2024. California still heavily relies on fossil fuels, nuclear power, and electricity imports for most of the year.
The situation is better in Europe, particularly Spain, where renewables provide at least half the load in 76% of all hours. But even there, the remaining hours require conventional power sources.
<h2 class="wp-block-heading">The Economics Are Not There Yet</h2>
Another cold reality: Electricity still costs 2-4 times more per unit of energy than natural gas for industrial consumers across countries. This explains why the electricity share of US industrial energy consumption has remained flat for decades despite advances in technology.
The economic gap slows electrification, which in turn slows decarbonization. Without electrification, it is hard to decarbonize energy-intensive industries using green grid electrons.
The Trump administration is clearly shifting priorities away from renewables to fossil fuels, national security, and inflation fighting.
This will likely mean scaled-back renewable subsidies, potentially reducing the energy bill by as much as $650 billion, about two-thirds of the original projected costs.
While this shift will not halt the renewable transition, it will likely slow its already gradual pace in the US.
For investors, the message is clear: Despite the excitement around clean energy, traditional energy is not going anywhere soon.
Human prosperity will remain inextricably linked to affordable natural gas and other fossil fuels for many years.
This does not mean avoiding renewable investments (they are growing steadily), but it does suggest maintaining exposure to traditional energy companies with strong balance sheets and reasonable valuations. The transition is happening on a timeline measured in decades, not years.
Remember, in markets as in energy transitions, patience and perspective are virtues that pay dividends. The infrastructure supporting our daily lives changes more like a battleship turning than a sports car—gradually, deliberately, and with tremendous momentum in both directions.
Let me tell you something that Wall Street&#8217;s green energy cheerleaders will not. Midstream oil and gas assets will be critical infrastructure for the next half-century, regardless of how many solar panels we install.
Pipelines, storage facilities, processing plants and terminals represent the circulatory system of our energy economy, and their importance will not diminish anytime soon.
With global energy demand projected to rise another 25% by 2050, according to conservative estimates, these assets will continue generating steady cash flows and dividends while the renewable transition inches forward at its glacial pace.
The beauty of midstream assets lies in their toll-road business model. They get paid based on volume, not commodity prices. While upstream producers ride the rollercoaster of oil and gas prices, these midstream workhorses collect their fees regardless of whether a barrel of oil costs $40 or $140.
This is precisely why smart investors seeking income and inflation protection should maintain significant exposure to these assets.
Companies with irreplaceable pipeline routes, long-term contracts with inflation adjustments, and strategic export terminals will continue rewarding shareholders with distributions that dwarf treasury yields for decades to come.
Perhaps most importantly, these midstream assets will serve as the bridge between our fossil fuel present and whatever energy future eventually materializes. Looking at the actual data instead of wishful thinking, it is clear that natural gas, which requires extensive midstream infrastructure, will remain critical not just for baseload power generation but as the essential backup for intermittent renewable sources.
Even as renewable capacity grows, the need for reliable gas delivery during Dunkelflaute events (those periods of low wind and solar output) becomes more critical, not less.
&nbsp;The companies that own and operate this infrastructure are not dinosaurs awaiting extinction—they are adaptable energy logistics specialists whose assets will be repurposed and utilized throughout any transition, however long it takes.
Using our new Benzinga Ranking system and the scanning tool on Benzinga Pro, I found two of the best collections of midstream assets that are trading at bargain-basement prices.
<h2 class="wp-block-heading">Energy Transfer</h2>
Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) represents exactly the kind of misunderstood, undervalued asset I&#8217;ve built my career finding before Wall Street wakes up. This midstream behemoth operates over 125,000 miles of pipeline infrastructure that touches virtually every major U.S. energy basin. While the ESG crowd has been busy shunning anything with fossil fuel exposure, ET has been quietly throwing off mountains of cash flow, trading at a ridiculous 8.2x price to free cash flow ratio, a valuation you typically only see during financial crises, not economic expansions.
The company&#8217;s 7.04% dividend yield is not just substantial; it is sustainable and growing, backed by distribution coverage above 1.7x. This is not your typical yield trap; it is an ATM for patient investors.
What most analysts miss about Energy Transfer is how its integrated asset footprint creates operational synergies that standalone operators simply cannot match. From natural gas gathering in the Permian to NGL fractionation to crude and refined product transportation, ET&#8217;s diversified operations provide multiple paths to growth regardless of which hydrocarbons dominate the energy mix.
Management has learned the hard lessons of overexpansion and now focuses on optimizing existing assets, reducing debt, and returning capital to unit holders. The inevitable consequence will be multiple expansions as the market finally recognizes that ET is not just surviving the energy transition.
&nbsp;It is positioned to facilitate whatever form it ultimately takes.
<h2 class="wp-block-heading">Plains All American Pipeline</h2>
Plains All American Pipeline (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is North America&#8217;s premier crude oil logistics provider, with strategically positioned assets throughout the continent&#8217;s most productive basins.
With approximately 7.5x free cash flow and a robust 7.6% dividend yield, PAA offers the value proposition that has historically generated substantial returns for investors willing to look past the anti-hydrocarbon narrative.
What separates Plains from its peers is its unmatched crude oil gathering and transportation network in the Permian Basin—the crown jewel of U.S. oil production that continues defying pessimistic forecasts year after year.
This focused strategy gives PAA exceptional leverage to continued Permian growth without the capital expenditure burdens that plague many competitors.
The company&#8217;s management team has significantly transformed over the past few years, reducing debt by billions and streamlining operations to focus on its core competencies.
Unlike many midstream operators who overextended during the shale boom, Plains has right-sized its operation and balance sheet to withstand market volatility while maintaining its generous payouts. The market continues to price PAA as if U.S. oil production is on the verge of permanent decline, ignoring the reality that America&#8217;s oil output continues to set records even as renewables grow.
For income investors seeking both current yield and potential capital appreciation, Plains offers the rare combination of deep value, operational excellence, and strategically vital assets that will remain essential infrastructure regardless of how quickly or slowly the energy transition unfolds. This is not speculation—it is investing in the physical assets needed to meet energy demands for decades to come.
<h2 class="wp-block-heading">The Trades You Can't Miss This Earnings Season</h2>
Earnings season is about to begin, and it's already creating major market moves. Matt Maley, with over 35 years of experience on Wall Street, is hosting a live webinar on Wednesday, April 2, at 6 PM ET, where he'll reveal the setups and strategies he's using to turn volatility into massive profits. Learn how to spot the highest-potential earnings trades and avoid the mistakes that could cost you big. If you want to trade earnings season like a pro, don't miss this session. Secure <a href="https://events2.benzinga.com/matt-maley-webinar-wed-apr2-2025-registration">your spot </a>now.
Photo: Shutterstock

Opinion

2 Income Stocks Reveal Why Solar Power Isn't Here Yet

<h3>Gainers</h3>
<ul>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares increased by 12.0% to $0.84 during Tuesday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) shares increased by 10.23% to $1.4. The market value of their outstanding shares is at $15.0 million. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) stock rose 6.37% to $0.51. The market value of their outstanding shares is at $8.5 million. </li>
<li>Oriental Culture Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCG#NASDAQ">OCG</a>) shares increased by 5.71% to $3.33. The company's market cap stands at $61.8 million. </li>
<li>MoneyHero (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) shares rose 5.38% to $0.84. The company's market cap stands at $33.1 million. </li>
<li>trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) stock moved upwards by 4.45% to $4.69. The company's market cap stands at $327.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock fell 42.6% to $0.06 during Tuesday's after-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Global Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GITS#NASDAQ">GITS</a>) shares declined by 41.03% to $0.69. The company's market cap stands at $1.8 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock declined by 4.59% to $0.21. The company's market cap stands at $3.0 million. </li>
<li>Grupo Televisa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TV#NYSE">TV</a>) stock decreased by 4.52% to $1.69. The market value of their outstanding shares is at $904.9 million. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) shares fell 4.27% to $0.6. The company's market cap stands at $10.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock decreased by 4.19% to $1.83. The market value of their outstanding shares is at $102.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEHL

BLMZ

CMLS

DRCT

GITS

MITQ

NIPG

TRVG

12 Communication Services Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 26.7% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 11.92% to $1.22. The market value of their outstanding shares is at $19.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 10.24% to $0.67. The company's market cap stands at $97.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares moved upwards by 8.88% to $0.24. The company's market cap stands at $11.5 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 8.58% to $0.76. The market value of their outstanding shares is at $2.1 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) shares increased by 6.96% to $0.34. The market value of their outstanding shares is at $10.9 million. As per the press release, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 17.9% to $2.15 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 17.63% to $0.36. The company's market cap stands at $1.0 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 14.57% to $0.24. The company's market cap stands at $10.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 10.32% to $26.0. The market value of their outstanding shares is at $338.3 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 9.29% to $0.05. The market value of their outstanding shares is at $7.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 7.56% to $0.21. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

BIAF

CODX

DHAI

GCTK

HCWB

OCEA

RSLS

TNFA

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) stock increased by 21.4% to $3.97 during Tuesday's after-market session. The market value of their outstanding shares is at $189.5 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock rose 10.85% to $2.45. The company's market cap stands at $81.8 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) stock moved upwards by 10.02% to $0.55. The market value of their outstanding shares is at $6.5 million. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares moved upwards by 6.42% to $1.15. The market value of their outstanding shares is at $1.4 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares moved upwards by 5.66% to $0.45. The company's market cap stands at $5.7 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares moved upwards by 5.45% to $2.9. The market value of their outstanding shares is at $37.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock declined by 8.8% to $1.14 during Tuesday's after-market session. The company's market cap stands at $18.5 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares declined by 7.94% to $3.83. The market value of their outstanding shares is at $2.2 million. </li>
<li>Smart Powerr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) shares fell 5.23% to $0.62. The market value of their outstanding shares is at $15.0 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares decreased by 4.67% to $0.29. The company's market cap stands at $56.5 million. The company's, Q4 earnings came out yesterday. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares fell 4.27% to $0.88. The company's market cap stands at $2.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Aeries Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) shares fell 4.15% to $0.55. The company's market cap stands at $24.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Advanced Environmental Recycling Technologies

AERT

CREG

CYCU

DXST

FTCI

LICN

LNZA

NEOV

NVVE

TTEC

UGRO

XPON

12 Industrials Stocks Moving In Tuesday's After-Market Session

Press Releases

Investigation Alert: Nano Nuclear Energy, New Fortress Energy, Domino's Pizza and GitLab Inc - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Kuehn Law Encourages Investors of Gitlab Inc. to Contact Law Firm

GitLab To Announce Fourth Quarter and Full Fiscal 2025 Financial Results

GitLab Chief Executive Officer Bill Staples and GitLab Chief Financial Officer Brian Robins to Present at the Morgan Stanley Technology, Media & Telecom Conference

GitLab Chief Financial Officer Brian Robins to Present at the 2025 Cantor Fitzgerald Global Technology Conference

GitLab Reports Fourth Quarter and Full Fiscal Year 2025 Financial Results

GITLAB INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GitLab Inc. - GTLB

GITLAB INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GitLab Inc. - GTLB

Comments

GitLab

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌